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Introduction 
Follicular lymphoma (FL) is the most frequent indolent
lymphoma in the Western world and accounts for approxi-
mately 20-40% of all B-cell lymphomas.1 Pediatric FL is con-
sidered a variant of FL that differs from adult FL with an
increased proportion exhibiting high-grade histology and
most cases presenting clinically as localized and curable dis-
eases.2-4 Moreover, pediatric FL differs genetically from their
adult counterpart.2 The genetic hallmark of adult FL, the
translocation t(14;18)(q32;q21) affecting the BCL2 gene is
hardly ever present in pediatric FL.2,3 Overall, and in contrast
to adult FL, the genetic events associated with pediatric FL
pathogenesis and prognosis have not yet been defined, with
the notable exception of those pediatric cases carrying an
IRF4 translocation.4 Therefore, we applied array-comparative
genomic hybridization (aCGH) and molecular inversion
probe (MIP) assay adapted for formalin-fixed, paraffin-
embedded (FFPE) tissues to FL of 18 patients diagnosed up to
the age of 18 years. 
Design and Methods
The study included 18 pediatric FL lacking an IRF4 translocation
with available FFPE tissue diagnosed in patients aged up to 18 years;
the clinicopathological features of 10 of these cases have been report-
ed previously.3 With the exception of one case with only focal involve-
ment by lymphoma (pFL13), the tumor cell content exceeded 50% in
the evaluable samples. Eleven of 18 patients were treated according to
NHL-BFM group multicenter trials,5,6 whereas 7 were treated accord-
ing to different treatment strategies. Clinical and histopathological
data are summarized in the Online Supplementary Appendix and Online
Supplementary Table S1.
DNA was extracted from FFPE tissue blocks using a phenol-chloro-
form extraction method.7 Fourteen cases were hybridized on the MIP-
assay using Oncoscan FFPE Express custom service (Affymetrix, Santa
Clara, CA, USA).8 Thirteen cases were analyzed using Agilent 244K
array (Agilent Technologies, Santa Clara, CA, USA), including 9 cases
simultaneously analyzed by MIP-assay (Online Supplementary
Appendix and Online Supplementary Figure S1). Copy number (CN)
plots were generated by the use of Nexus 6.0 beta Discovery Edition
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Pediatric follicular lymphoma is a rare disease that differs genetically and clinically from its adult counterpart. With
the exception of pediatric follicular lymphoma with IRF4-translocation, the genetic events associated with these
lymphomas have not yet been defined. We applied array-comparative genomic hybridization and molecular inver-
sion probe assay analyses to formalin-fixed paraffin-embedded tissues from 18 patients aged 18 years and under
with IRF4 translocation negative follicular lymphoma. All evaluable cases lacked t(14;18). Only 6 of 16 evaluable
cases displayed chromosomal imbalances with gains or amplifications of 6pter-p24.3 (including IRF4) and deletion
and copy number neutral-loss of heterozygosity in 1p36 (including TNFRSF14) being most frequent. Sequencing
of TNFRSF14 located in the minimal region of loss in 1p36.32 showed nine mutations in 7 cases from our series.
Two subsets of pediatric follicular lymphoma were delineated according to the presence of molecular alterations,
one with genomic aberrations associated with higher grade and/or diffuse large B-cell lymphoma component and
more widespread disease, and another one lacking genetic alterations associated with more limited disease. 
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software (Biodiscovery, El Segundo, CA, USA). Gains and losses
were evaluated by 2 different observers. 
Fluorescence in situ hybridization (FISH) analyses were per-
formed for the detection of breakpoints or gene fusions and for
verification of gains in chromosome 6p25 as previously
described.9,10 For this purpose, commercially available MYC BAP,
BCL2 BAP, IGH BAP and BCL6 BAP probes, an IGH/BCL2 double-
color double-fusion probe (all Abbott/Vysis, Downers Grove, IL,
USA) and a previously designed FISH probe for IRF4 (BAP)4 were
used.
Potential point mutations detected by MIP-assay in PIK3CA,
FBXW7, ABL1, NOTCH1, STK11 and PTEN were also analyzed
by direct sequencing using ABI PRISM 3100 Genetic Analyzer sys-
tem (Applied Biosystems, Foster City, CA, USA). Details are
described in the Online Supplementary Appendix. Similarly, the cod-
ing exons of TNFRSF14 (Online Supplementary Table S2) and
Tyr641 EZH24 were also analyzed by direct sequencing in the
whole series. 
Clonality analysis was performed investigating the framework
1-3 regions of the immunoglobulin heavy chain (IGH) according to
the Biomed-2 protocol.11
Statistical analyses were performed using PASW Statistics soft-
ware version 18 (SPSS Inc., Chicago, IL, USA). 
The study was performed in the framework of the BFM-NHL
trial, for which central and local institutional review board (IRB)
approvals were obtained, and according to the guidelines of the
MMML Network Project of the Deutsche Krebshilfe (approved by
the Institutional Review Board of the Medical Faculty Kiel under
403/05).
Results and Discussion
Pediatric FL is a rare disease that differs from its adult
counterpart both genetically and clinically.3 We recently
described a distinct subset of germinal center B-cell lym-
phomas including FL characterized by the presence of
IRF4 gene translocations, predominately affecting children
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Figure 1. (A) Copy number (CN) profiles of 16
pediatric FL. In the x-axis the chromosomes
are represented horizontally from 1 to 22, in
the y-axis the percentage of cases showing
the CN alterations. Gains are represented in
the positive y-axis and colored in yellow,
whereas losses are represented in the nega-
tive y-axis in blue. The most frequent CN
alteration was gain/amplification of 6pter-
p24.3. (B) Molecular Inverse Probe (MIP)-
assay profiles showing CN neutral loss of het-
erozygosity (CNN-LOH) at 1p36 in the pFL7,
pFL10 and pFL14 cases. Allelic events are
displayed along the x axis (from pter to qter).
Germline homozygosity (e.g. AA, BB alleles)
at a given SNP results in calls at the 0 and 1
levels, respectively, germline heterozygosity
(AB-alleles) in calls around 0.5 (y-Axis: 0-1).
CNN-LOH in the tumor leads to loss of calls
around 0.5 and to the presence of allelic
imbalance calls derived from a sum of het-
erozygous normal cell (AB) and homozygous
tumor cell (AA or BB) calls for a given locus
resulting in values between 0-0.5 or 0.5-1
depending on the amount of cells carrying
the aberration. Thus, in the areas with only
contribution from one parent (LOH/CNN-
LOH), two bands should we expected (0% and
100%->0 and 1.0. y Axis). In the 3 cases
(pFL7, pFL10, pFL14), the probes did not
reach such thresholds because alterations
are detected to be in mosaicism (not germ-
line alterations). (C) Summary data of the
FISH, CN, CNN-LOH, 1p36, TNFRSF14, EZH2
mutation, IGH clonality, BCL2 expression
analyses and DLBCL component for the 18
pediatric FL patients. FISH was considered
positive when splits in the BCL2, BCL6, MYC,
IRF4 and IGH genes were detected; CN, when
chromosomal imbalances were found by
MIP-assay or aCGH; 1p36, when CNN-LOH
(detected by MIP-assay) or deletions (by MIP-
assay and/or aCGH) were observed at that
region; TNFRSF14 and EZH2, when mutations
were found by direct sequencing; IGH clonali-
ty was positive when clonal IGH chain gene
rearrangement was detected by PCR; BCL2
expression was positive when more than
25% of the cells were positive. In pFL2 only
the region FR3 was evaluable in the IGH PCR
reaction. In pFL18 IGH monoclonality was
based on an analysis performed in an outside
laboratory. CNN-LOH could not be determined
in cases 1, 2, 12, 16, 17, and 18. 
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and young adults.4 In the present study, we determined
genetic aberrations in a series of 18 pediatric FL cases lack-
ing such IRF4 translocation. Of these 18 FL, 9 (50%) were
classified as FL grade 3a (FL3a), 6 (33%) as grade 3b (FL3b),
one (6%) as grade 3 unclassified, and 2 (11%) as grade 2.
Areas of grade 1 or 2 FL as a second lymphoma compo-
nent were detectable in 4 cases diagnosed as FL3a (22%),
while a simultaneous diffuse large B-cell lymphoma
(DLBCL) component was noted in 4 (22%) cases, 3 diag-
nosed as FL3b and one as FL3a. Seven patients presented
with stage I disease, 5 were rated as stage II and 3 suffered
from stage III disease. Tumor localization in or dissemina-
tion to the neck region was the most frequent presentation
(11 of 18). Notably, the present series of pediatric FL seems
to differ from those of other recently published series with
regard to sites of involvement, clinical stage and presence
of a DLBCL component.12,13 This might be due to the fact
that the present series predominately reflects population-
based assessment for a pediatric clinical trial rather than
data collected from consultation centers. The patients
were predominantly male (61%), with a median age of
12.1 years (range 6-18 years). All cases evaluable for the
respective analyses lacked BCL2 breakpoints and/or IGH-
BCL2 fusion and MYC breakpoints by FISH. Breaks in
IGH locus occurred in 4 of 15 evaluable cases whereas a
BCL6 break occurred in one of 17 cases (Online
Supplementary Table S1).
CN determination by aCGH and/or MIP-assay was suc-
cessful in 16 of the 18 FL (89%) (Online Supplementary
Figure S1). Eight samples were analyzed on both CN plat-
forms showing a good agreement (with 7 showing the
same imbalances by both platforms). Only one case
(pFL12) with low quality DNA showed differences
between platforms, with a chromosome 7 gain only
detectable using MIP-assay. Only 6 of 16 evaluable pedi-
atric FL (37%) displayed CN alterations and/or copy num-
ber neutral-loss of heterozygosity (CNN-LOH), with a
mean of 6.5 aberrations per case (Figure 1A and Online
Supplementary Tables S3 and S4). These findings contrast
with adult FL, where the number of cases with chromoso-
mal imbalances14 and CNN-LOH15 is higher (71.6% vs.
37.5%; P=0.01, and 76% vs. 40%; P=0.05, respectively).
The most frequent imbalance in pediatric FL was 6pter-
p24.3 gain including amplification (3 of 6 aberrant cases).
Despite IRF4 being shown by FISH to be included in the
gained region (Online Supplementary Figure S2), no consis-
tent expression of IRF4/MUM1 was observed in these
cases (2 of 3 expressed IRF4/MUM1). Remarkably, 3 cases
showed CNN-LOH in 1p36.32-p36.13 region (pFL7,
pFL10, and pFL14) (Figure 1B) and another one showed a
deletion of the whole 1p arm (pFL5). In comparison with
3 previously published pediatric FL cases positive for IRF4
translocation,16 cases positive for the translocation were
significantly more complex in terms of CN alterations
than the IRF4 negative pediatric FL (7 alterations/case vs.
2.4 alterations/case; P=0.029) (Online Supplementary Figure
S3). Of note, IRF4 translocation positive cases presented
more frequently gains of 11q and deletions of 17p arm
including the TP53 gene. Furthermore, one of the cases
showed a deletion at 1pter-p35.2 with a transition muta-
tion in the TNFRSF14 gene (g.343C>T, T15I) (data not
shown).
Both the gain in 6p as well as CNN-LOH/loss of 1p
seem not to be exclusive to pediatric FL, since they have
also been described in adult FL independently of the pres-
ence of t(14;18) translocation.14 In fact, deletions and
CNN-LOH of 1p36 have been described as one of the
most frequent secondary genetic aberrations in adult FL15
and are considered a significant predictor of poor overall
survival.17 The minimal region of loss/CNN-LOH in 1p36
contains the candidate gene TNFRSF14, encoding a mem-
ber of the tumor necrosis factor receptor (TNFR) super-
family which has been shown to be recurrently mutated
in adult FL.18,19 Sequencing of TNFRSF14 in the 4 pediatric
FL cases with 1p36 aberration revealed 3 to carry muta-
tions, including one missense mutation in exon 1
(g.340C>G, S14C; pFL7), two splice donor site mutations
of the exon 1 (g.370T>C and g.370T>A; pFL7 and pFL10)
and one nonsense mutation in exon 5 (g.4336C>T,
Q180X; pFL14). Extension of the TNFRSF14 mutation
Genetic events in pediatric FL
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Figure 2. (A-H) Histomorphological
features of case pFL11 (FL3a) (A-D)
without aberrant genotype and case
pFL14 (FL3a) (E-H) with aberrant
genotype: in both cases an infiltration
of the lymph node by enlarged abnor-
mal follicles as well as remnants of
normal reactive follicles (indicated by
arrows) are seen in the low magnifi-
cation (A,E, H&E x 25). The neoplastic
follicles lack a clear “starry sky” pat-
tern as well as the demarcation by a
mantle zone (B,F, H&E x 100). The fol-
licles consist of centroblasts and cen-
trocytes (C,G, H&E x 1000). The lack
of zonation is seen with immunohis-
tochemistry for the proliferation
marker Ki67 (D, H, Ki67 x 100), nev-
ertheless a hot spot of proliferation
can be observed in H.
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screening to the remaining cases revealed 5 non-synony-
mous mutations in 4 pediatric FL without 1p36 aberration
(Online Supplementary Table S5). Thus, 7 of 17 pediatric FL
contain mutations in TNFRSF14 making this the most
recurrent change in this disease known so far. In order to
identify the incidence of previously described EZH2 pro-
tein mutation (Tyr641),20 the whole series of pediatric FL
was sequenced; 2 cases were found with mutations (pFL3
and pFL15) (Online Supplementary Table S3). 
A synopsis of the obtained molecular profiling results
revealed that all cases with breaks in IGH or BCL6 also
showed CN alterations and/or mutations in TNFRSF14 or
EZH2 genes. Based on the results of the molecular analy-
ses, two groups of FL could be distinguished: one contain-
ing the genetically aberrant pediatric FL and another one
comprising the pediatric FL without any aberration (Figure
1C). The absence of genomic aberrations due to a low
content of tumor cells was ruled out in all the patients
(>50% tumor cell content) except in case pFL13 (20%).
Nevertheless, we cannot exclude the possibility that the
percentage of subclonal cells harboring a genetic aberra-
tion might influence the grouping. 
Studying IGH clonality revealed that the 2 samples with
polyclonal pattern (pFL2 and pFL11) were in the set lacking
genomic aberrations. In one of the cases (pFL2), only the
FR3 region was evaluable in the central IGH clonality
analysis. Therefore, we cannot exclude that clonality could
be detectable with FR1 or FR2 primers. Despite the poly-
clonal pattern, both cases displayed clear histomorpholog-
ical features of malignancy with subtotal effacement of the
underlying lymphnode structure, destruction of the normal
germinal center architecture, loss of follicle mantles and
abnormaly enlarged in part confluent neoplastic follicles.
Although there is general agreement regarding the absence
of BCL2-rearrangement in pediatric FL at the molecular
level, reported levels of BCL2 protein expression vary con-
siderably ranging from 0% to 50%.2,3,12,13 In our series, the
majority of the cases (12 of 15) expressed the protein to
some degree. The relatively high proportion of BCL2
expressing cases in our series, in comparison to previous
reports, might be due to the selection criteria applied, i.e.
The inclusion of FL cases with simultaneous DLBCL com-
ponent and the exclusion of cases with IRF4 translocations.
No correlation was found between BCL2 expression and
the presence of genetic aberrations. 
Comparing the two groups defined by the genomic
aberration status with clinical data, the group with aberra-
tions was enriched for patients showing higher grade his-
tology and higher stage disease patterns. For example,
advanced disease stage (>II), grade 3b or a DLBCL compo-
nent occurred almost exclusively in the genetically altered
group (Table 1). In contrast, lack of genetic aberrations
occurred in clinical stages I and II and was never associat-
ed with a DLBCL component, although this was not sta-
tistically significant probably because of the low number
of cases (Figure 1C). Notably, comparing cases with and
without neck region tumor localization/involvement, the
second group was significantly associated with the pres-
ence of genomic aberrations (P=0.03). Previous studies
have shown that tonsillar pediatric FL are nearly always
positive for MUM1/IRF4.13 Nevertheless, the present series
shows few cases (pFL4 and pFL 15) with tonsillar involve-
ment, which at least in part is likely due to exclusion of the
cases harboring IRF4 translocations known to be strongly
MUM1 positive.4
Despite these biological differences, the overall survival
was comparable between the groups with genomic aber-
rations and without them (Table 1 and Online
Supplementary Table S1). This might be associated with the
fact that most patients (12 of 16), besides the diagnostic
lymph node excision, received treatment with multi-agent
chemotherapy. The whole series showed an excellent sur-
vival with all patients being alive at the last follow up
independently of the biological subgrouping, with a medi-
an follow up of 60.6 months.
In summary, we describe the pattern of genomic imbal-
ances in IRF4 translocation negative pediatric FL and iden-
tify recurrent mutation of TNFRSF14. Moreover, we show
genetic alterations to distinguish two subsets of pediatric
FL. In the first subset genomic aberrations could be identi-
fied with the techniques applied and this subset is associ-
ated with higher grade and/or diffuse large B-cell lym-
phoma component and more widespread disease. The
second group lacks genetic alterations detectable with the
present approaches and is associated with a more limited
disease. Despite the absence of genomic aberrations, these
I. Martin-Guerrero et al.
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Table 1. Comparison of clinical and biological characteristics of pedi-
atric follicular lymphoma (FL) with genomic aberrations versus pedi-
atric FL without aberrations.
Clinical and Ped FL with Ped FL without P  
biological genomic genomic
characteristics aberrations aberrations 
Sex ratio (M:F) 1.2:1 2.5:1 0.64 
Age (median) 12.1 12 0.97 
Grade FL
1-2 1 1
3a 4a 5b 0.313b 5 1
Grade 3 unknown 1 -
Stage
I 2 5
II 3 2 0.11
III 3 0
nd 3 -
DLBCL component 
No 7 7 0.12Yes 4c 0
Localization 
Neck region 4 7 
Other regions 4 0 0.03
Both 3 0
Remnants of reactive B follicles
No 5 2
Yes 5 5 0.38
nd 1 -
Marginal zone differentiation
No 9 4 0.33
Yes 2 3
Ki67 (%) 55d 54e 0.99
Tumor cell content (%) 76.4 67.9 0.32 
Median follow up 73.8e 43.6 0.21
(months) 
nd: not determined; DLBCL: diffuse large B-cell lymphoma; M: male; F: female. aOne case
with FL1/2 as a second lymphoma component; bThree cases with FL1/2 as a second
lymphoma component; cCase pFL8 present “starry sky”/Burkitt-like pattern; dData not
available in one case; eData not available in 2 cases.
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cases resembled FL by their histopathological features
(Figure 2). The absence of genetic aberrations detectable
with the methods used in the current study does not nec-
essarily mean that these lesions are completely devoid of
genomic aberrations. Since the histopathology of these
lesions is not compatible with reactive conditions, it
seems possible that a higher resolution of genomic analy-
sis such as next generation sequencing will reveal aberra-
tions. In turn, the presence of genetic aberrations does not
ultimately prove malignancy as documented, for example,
in monoclonal gammopathy of undetermined significance
(MGUS).1 Indeed, it could well be that at least a subset of
pediatric FL could similarly represent monoclonal follicu-
lar proliferations of undetermined significance.
Given that the patients included in this study have been
treated independently of the genomic aberration status and
show excellent survival rates, we cannot, therefore, com-
ment on whether the detectability or pattern of genomic
differences also translate into a different clinical outcome
or whether the genetically normal appearing FL might be
treated less intensively or if a “watch and wait” approach
can be adopted in completely resected local disease. 
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